Patents Issued in March 7, 2017
-
Patent number: 9586996Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.Type: GrantFiled: April 28, 2011Date of Patent: March 7, 2017Assignee: ESPERANCE PHARMACEUTICALS, INC.Inventors: Hector Alila, Carola Leuschner
-
Patent number: 9586997Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.Type: GrantFiled: September 19, 2011Date of Patent: March 7, 2017Assignees: BioNtech Cell & Gene Therapies GmbH, Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gemeinnutzige GmbHInventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
-
Patent number: 9586998Abstract: The invention provides methods for propagating a monkey adenovirus in a cell, including a human cell, comprising one or more gene products isolated from a human adenovirus. Also provided are methods for propagating wherein the monkey adenovirus comprises a nucleic acid sequence encoding a human adenovirus gene product. The invention further provides a monkey adenovirus, including a replication-deficient monkey adenovirus, obtained by such propagation methods.Type: GrantFiled: August 4, 2015Date of Patent: March 7, 2017Assignee: GenVec, Inc.Inventors: Jason Gall, Douglas Brough, Christoph Kahl, Duncan McVey
-
Patent number: 9586999Abstract: Disclosed are compositions and methods related to improving pharmacological properties of bioactive compounds targeting nervous system.Type: GrantFiled: December 2, 2014Date of Patent: March 7, 2017Assignee: University of Utah Research FoundationInventors: Grzegorz Bulaj, H. Steve White
-
Patent number: 9587000Abstract: The present application describes a cell that has integrated into its genome fusion molecule V16-CREB.Type: GrantFiled: May 12, 2015Date of Patent: March 7, 2017Inventor: Sung Ho Hahm
-
Patent number: 9587001Abstract: Disclosed are knottin peptides containing non-natural amino acids so that they can be formed by chemical conjugation into two or more knottin monomers. The knottin monomers comprise a non-natural amino acid such as an aminooxy residue within the polypeptide sequence. The exemplified dimers were produced by oxime formation between two aldehyde groups present on a polyether linker and an aminooxy functional group that was site-specifically incorporated the knottin. Knottins variants based on EETI (Ecballium elaterium trypsin inhibitor) and AgRP (Agouti-related protein) were engineered to contain integrin-binding loops. These dimers were shown to have increased binding strength to integrins on U87MG tumor cells, achieving significant increases in inhibition of cell adhesion and proliferation. Also disclosed are knottin monomers comprising an aminooxy residue; these may be conjugated to molecules such as doxorubicin.Type: GrantFiled: October 18, 2013Date of Patent: March 7, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jennifer R. Cochran, Jun Woo Kim, Frank V. Cochran
-
Patent number: 9587002Abstract: This invention relates to a compound that induces or activates telomerase activity based on the nucleotide sequence of the GSE 24.2 fragment of dyskerin or the protein or peptide sequence encoded by said nucleotide sequence. Another part of the invention relates to vectors that comprise said sequence and cells transformed thereby, and pharmaceutical compositions that contain all these elements. These compositions may be used in the treatment of diseases from the following group: ageing or acceleration of ageing, neurodegenerative diseases and dyskeratosis congenita.Type: GrantFiled: June 16, 2015Date of Patent: March 7, 2017Assignees: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, UNIVERSIDAD AUTONOMA DE MADRID—FUNDACION GENERAL, UNIVERSIDAD POLITECNICA DE VALENCIAInventors: Rosario Perona Abellon, Rosario Machado Pinilla, Leandro Sastre Garzon, Isabel Sanchez Perez, Jose Ramon Murguia Ibanez
-
Patent number: 9587003Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncology-related polynucleotides, oncology-related primary transcripts and oncology-related mmRNA molecules.Type: GrantFiled: February 4, 2016Date of Patent: March 7, 2017Assignee: ModernaTX, Inc.Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
-
Patent number: 9587004Abstract: This document provides methods and materials related to natriuretic polypeptides and the use of natriuretic polypeptides to treat cardiovascular and/or renal conditions. For example, chimeric polypeptides having at least one amino acid segment (e.g., N-terminus tail, ring structure, C-terminus tail, or a combination thereof) of a natriuretic peptide (e.g., ANP, BNP, CNP, URO, or DNP) and an amino acid segment of an angiotensin polypeptide (e.g., Ang-(1-7)) are provided.Type: GrantFiled: August 9, 2016Date of Patent: March 7, 2017Assignee: Mayo Foundation for Medical Education and ResearchInventors: Candace Y. W. Lee, John C. Burnett, Jr.
-
Patent number: 9587005Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.Type: GrantFiled: December 28, 2015Date of Patent: March 7, 2017Assignee: Indiana University Research and Technology CorporationInventors: Richard D. DiMarchi, Brian P. Ward
-
Patent number: 9587006Abstract: Herein is reported a method for producing of a polypeptide conjugated to one poly (ethylene glycol) comprising a) providing a nucleic acid encoding an expression construct comprising in 5? to 3? direction a nucleic acid encoding a polypeptide, and a nucleic acid encoding a trypsin site of SEQ ID NO: 01, b) expressing the nucleic acid of a) in a cell and recovering the expression construct from the cell and/or the cultivation medium, c) providing a target peptide with an amino acid sequence of SEQ ID NO: 02 covalently conjugated to a poly (ethylene glycol) at the C-terminal lysine residue, d) incubating the expression construct and the target peptide with the trypsin mutant D189K, K60E, N143H, E151H, and e) recovering and thereby producing the polypeptide conjugated to one poly (ethylene glycol) from the incubation mixture.Type: GrantFiled: February 4, 2011Date of Patent: March 7, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Friederike Hesse, Eva Hoess, Stephanie Mueller, Eva Maria Trost-Gross
-
Patent number: 9587007Abstract: The present disclosure relates to CTLA4 proteins and uses of such proteins, for example to treat diseases associated with the dysregulation of immune responses.Type: GrantFiled: October 27, 2014Date of Patent: March 7, 2017Assignee: AbbVie Biotherapeutics Inc.Inventors: Yoshiko Akamatsu, Veronica Juan, Robert B. Dubridge
-
Patent number: 9587008Abstract: Methods for producing cell lines with high levels of biologically active recombinant vitamin K dependent proteins are described. The transfected cell lines do not include heterologous genes for processing enzymes and are not subject to selection pressure such as methotrexate resistance. Cell lines producing Factor VII/VIIa and Factor IX are described. These cell lines can be used for isolation of Factor VII/VIIa and/or Factor IX for treatment of Hemophilia.Type: GrantFiled: September 3, 2014Date of Patent: March 7, 2017Assignee: APTEVO BIOTHERAPEUTICS LLCInventors: William N. Drohan, Michael J. Griffith
-
Patent number: 9587009Abstract: The invention relates generally to solid supports for chromatography. In specific embodiments the invention provides for solid supports suitable for affinity chromatography along with methods, systems and kits which use the same.Type: GrantFiled: July 7, 2014Date of Patent: March 7, 2017Assignee: EMD Millipore CorporationInventors: Nanying Bian, Senthil Ramaswamy, Neil Soice, Chen Wang, Yuan Wong
-
Patent number: 9587010Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.Type: GrantFiled: July 18, 2011Date of Patent: March 7, 2017Assignee: THE INSTITUTE FOR RESEARCH IN BIOMEDICINEInventor: Antonio Lanzavecchia
-
Patent number: 9587011Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines.Type: GrantFiled: November 11, 2015Date of Patent: March 7, 2017Assignee: Pomona Ricerca S.r.l.Inventors: Roberto Burioni, Massimo Clementi
-
Patent number: 9587012Abstract: In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.Type: GrantFiled: December 2, 2014Date of Patent: March 7, 2017Assignee: AARON DIAMOND AIDS RESEARCH CENTERInventors: David D. Ho, Yaoxing Huang, Jian Yu
-
Patent number: 9587013Abstract: The invention provides methods for isolating a modified peptide from a complex mixture of peptides, the method comprising the steps of: (a) obtaining a proteinaceous preparation from an organism, wherein the preparation comprises modified peptides from two or more different proteins; (b) contacting the preparation with at least one immobilized modification-specific antibody; and (c) isolating at least one modified peptide specifically bound by the immobilized modification-specific antibody in step (b). The method may further comprise the step of (d) characterizing the modified peptide isolated in step (c) by mass spectrometry (MS), tandem mass spectrometry (MS-MS), and/or MS3 analysis, or the step of (e) utilizing a search program to substantially match the spectra obtained for the modified peptide during the characterization of step (d) with the spectra for a known peptide sequence, thereby identifying the parent protein(s) of the modified peptide.Type: GrantFiled: April 23, 2013Date of Patent: March 7, 2017Assignee: Cell Signaling Technology, Inc.Inventors: John Rush, Hui Zhang, Xiangming Zha, Michael J Comb, Yi Tan
-
Patent number: 9587014Abstract: Provided are novel TAR DNA-binding proteins of 43 kDa (“TDP-43”)-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: October 26, 2012Date of Patent: March 7, 2017Assignees: Biogen International Neuroscience GmbH, University of ZürichInventors: Roger Nitsch, Christoph Hock, Maria Grazia Barenco Montrasio, Fabio Montrasio, Jan Grimm, Jean-Luc Baeriswyl, Paul Weinreb, Janaky Coomaraswamy, Omar Quintero-Monzon
-
Patent number: 9587015Abstract: Novel anti-human CTGF antibodies having excellent binding activity and/or neutralizing activity, as compared with conventional anti-human CTGF antibodies, are useful for treating various diseases in which human CTGF is involved in pathogenesis, including renal diseases such as chronic kidney disease and diabetic nephropathy.Type: GrantFiled: December 21, 2012Date of Patent: March 7, 2017Assignee: Astellas Pharma Inc.Inventors: Shoji Iwasaki, Ryuichi Moriya, Masayasu Yoshino, Koji Takakura
-
Patent number: 9587016Abstract: The present invention relates to methods and medicaments useful for pre-treatment, treatment, or amelioration of lung remodeling disease. Methods and medicaments for reducing, preventing, or reversing increased lung density, improving lung function, and increasing survivability in subjects having lung remodeling disease are also provided.Type: GrantFiled: June 17, 2015Date of Patent: March 7, 2017Assignee: FIBROGEN, INC.Inventor: Kenneth E. Lipson
-
Patent number: 9587018Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.Type: GrantFiled: September 30, 2015Date of Patent: March 7, 2017Inventors: Juan Carlos Almagro, William DuBell, Johann Fransson, Jose Pardinas, Gopalan Raghunathan
-
Patent number: 9587019Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.Type: GrantFiled: May 15, 2013Date of Patent: March 7, 2017Assignee: SEATTLE GENETICS, INC.Inventors: May Kung Sutherland, Maureen Ryan, Django Sussman, Patrick Burke, Scott Jeffrey
-
Patent number: 9587020Abstract: The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.Type: GrantFiled: March 9, 2016Date of Patent: March 7, 2017Assignee: The Regents of the University of CaliforniaInventors: Chia-Yung Wu, James Onuffer, Wendell A. Lim
-
Patent number: 9587021Abstract: CD3-binding molecules capable of binding to human and non-human CD3, and in particular to such molecules that are cross-reactive with CD3 of a non-human mammal (e.g., a cynomolgus monkey) are presented. Uses of such antibodies and antigen-binding fragments in the treatment of cancer, autoimmune and/or inflammatory diseases and other conditions are presented.Type: GrantFiled: May 16, 2012Date of Patent: March 7, 2017Assignee: MacroGenics, Inc.Inventors: Ling Huang, Leslie S. Johnson
-
Patent number: 9587022Abstract: Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.Type: GrantFiled: December 18, 2013Date of Patent: March 7, 2017Assignee: THE ROCKEFELLER UNIVERSITYInventors: Ruijiang Song, David D. Ho
-
Patent number: 9587023Abstract: The invention relates to recombinant monovalent antibodies which are heterodimers of a first protein chain comprising the variable domain of the heavy chain of an antibody of interest and the CH2 and CH3 domains of an IgG immunoglobulin and a second protein chain comprising the variable domain of the light chain of said immunoglobulin of interest and the CH2 and CH3 domains of said IgG immunoglobulin. These antibodies can be used in particular as therapeutic agents in all cases where monovalent binding to a ligand such a cellular receptor is required.Type: GrantFiled: January 13, 2010Date of Patent: March 7, 2017Assignees: OSE Immunotherapeutics, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Bernard Vanhove, Caroline Mary, Flora Coulon
-
Patent number: 9587024Abstract: The present invention provides an antibody or antigen-binding fragment thereof that binds ?v?3 integrin, as well as methods of use in the treatment of diseases and disorders.Type: GrantFiled: June 2, 2015Date of Patent: March 7, 2017Assignee: The University of North Carolina at Chapel HillInventors: David Clemmons, Laura Maile, Michael Naso, Francis J. Carr, Timothy D. Jones, Simon William Keen
-
Patent number: 9587025Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.Type: GrantFiled: December 10, 2012Date of Patent: March 7, 2017Assignee: The Rockefeller UniversityInventors: Jeffrey V. Ravetch, Andrew Pincetic
-
Patent number: 9587026Abstract: Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.Type: GrantFiled: February 7, 2014Date of Patent: March 7, 2017Assignee: Immunex CorporationInventors: Richard J. Armitage, Jose Carlos Escobar, Arvia E. Morris
-
Patent number: 9587027Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.Type: GrantFiled: September 24, 2014Date of Patent: March 7, 2017Assignee: MEDIMMUNE LIMITEDInventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Emma Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
-
Patent number: 9587028Abstract: The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.Type: GrantFiled: August 7, 2015Date of Patent: March 7, 2017Assignees: Dana-Farber Cancer Institute, Inc., Brigham and Women's HospitalInventors: Wayne A. Marasco, Jianhua Sui, Quan Zhu, De-Kuan Chang, Thomas S. Kupper
-
Patent number: 9587029Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.Type: GrantFiled: August 7, 2015Date of Patent: March 7, 2017Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
-
Patent number: 9587030Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.Type: GrantFiled: September 8, 2016Date of Patent: March 7, 2017Assignee: KYMAB LIMITEDInventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosma{hacek over (c)}
-
Patent number: 9587031Abstract: The present invention can provide a monoclonal antibody which comprises a heavy chain constant region which is IgG2 wherein valine at position 234, glutamine at position 237 and proline at position 331 are at least substituted with alanine, alanine and serine, respectively (numbering is based on the EU index of Kabat et al); has an agonist activity; and binds to human CD40.Type: GrantFiled: November 25, 2015Date of Patent: March 7, 2017Assignee: KYOWA HAKKO KIRIN CO., LTDInventors: Aki Matsushima, Hiroshi Namisaki, Shigenori Yagi
-
Patent number: 9587032Abstract: The present invention provides novel IgE antibodies useful for inhibiting or preventing metastatic cancer. Also provided are methods to inhibit tumor metastasis by modulating the activity of at least one non-tumor cell, treating a patient to inhibit or prevent tumor metastases of a primary solid tumor, treating metastatic carcinoma, reducing metastasis of carcinoma cells, and reducing the growth kinetics of a primary solid tumor or a metastasized cell or tumor.Type: GrantFiled: July 11, 2013Date of Patent: March 7, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Joseph A. Mollick, Pearline Teo, Paul J. Utz
-
Patent number: 9587033Abstract: Disclosed herein are novel antibodies specific to Tnk1 or variants thereof. Also disclosed are methods of using such antibodies. The methods include therapeutic methods against certain types of cancers or infections involving administration of novel antibodies or fragments thereof. Also, methods of using highly selective antibodies for detecting aberrant Tnk1 or functionally deficient Tnk1.Type: GrantFiled: November 15, 2011Date of Patent: March 7, 2017Assignee: University of Florida Research Foundation, Inc.Inventors: Hoare Kishalay, William Stratford May, Sarasija Hoare
-
Patent number: 9587034Abstract: Antibodies binding to junction regions between the CH4 and C?mX domains of membrane-bound IgE and uses thereof in treating IgE-mediated diseases such as allergic diseases.Type: GrantFiled: March 14, 2013Date of Patent: March 7, 2017Assignee: Academia SinicaInventors: Tse Wen Chang, Jiun-Bo Chen, Chien-Jen Lin, Nien-Yi Chen
-
Patent number: 9587035Abstract: The invention relates to the detection and quantification of 1-benzylpiperazine and its metabolites. The invention is underpinned by novel polyclonal antibodies with unique binding properties which enable immunoassay methods and kits for various applications.Type: GrantFiled: July 1, 2013Date of Patent: March 7, 2017Assignee: Randox Laboratories LimitedInventors: Elouard Benchikh, Ivan McConnell, Philip Lowry, Peter Fitzgerald
-
Patent number: 9587036Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.Type: GrantFiled: April 1, 2011Date of Patent: March 7, 2017Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Peter Kufer, Ralf Lutterbuese, Matthias Klinger, Petra Fluhr, Doris Rau, Susanne Hausmann, Carola Steiger, Tobias Raum, Patrick Hoffmann, Roman Kischel, Evelyne Schaller, Susanne Mangold
-
Patent number: 9587037Abstract: A process for recovering an esterified cellulose ether from a reaction product mixture obtained from a reaction of (a) a cellulose ether with (b) an aliphatic monocarboxylic acid anhydride or a di- or tricarboxylic acid anhydride or a combination of an aliphatic monocarboxylic acid anhydride and a di- or tricarboxylic acid anhydride, comprises the steps of (i) contacting the reaction product mixture with an aqueous liquid to precipitate the esterified cellulose ether from the reaction product mixture, (ii) isolating the precipitated esterified cellulose ether from the mixture obtained in step (i), and (iii) suspending the isolated esterified cellulose ether in an aqueous liquid to provide a suspension having a temperature of at least 28° C., and (iv) recovering the esterified cellulose ether from the suspension of step (iii).Type: GrantFiled: September 15, 2014Date of Patent: March 7, 2017Inventors: Oliver Petermann, Matthias Sprehe, Robert Appell, Robert Nilsson
-
Patent number: 9587038Abstract: The present invention relates to a process for producing microcellulose comprising a) acidifying fibrous cellulosic material, b) washing the acidified cellulosic material, c) optionally dewatering the washed cellulosic material, and d) hydrolyzing the washed or washed and dewatered cellulosic material under acidic conditions at a temperature of at least 120° C. and at a consistency of at least 8% on dry weight of the cellulose.Type: GrantFiled: June 6, 2011Date of Patent: March 7, 2017Assignee: Kemira OyjInventors: Erkki Iikka Sakari Rasanen, Leif Robertsen, Veli-Matti Vuorenpalo, Asko Karppi, Kari Parviainen, Olli Dahl, Kari Vanhatalo
-
Patent number: 9587039Abstract: Provided is a fluorine-containing macroinitiator, particularly a fluorine-containing macroinitiator that enables production of a fluorine-containing block copolymer containing a non-fluorine vinyl-based monomer having a long side chain. The fluorine-containing macroinitiator includes a polymer represented by the following formula (1) and having a number-average molecular weight of 3,000 to 100,000. In the following formula (1), R2, R3 and R4 are each a specific group, and Q is a polymer segment composed of a structural unit represented by the following formula (2). In the following formula (2), R1 is a hydrogen atom or a methyl group, Rf is a fluoroalkyl group having a specific structure, and k is an appropriate integer that is not 0.Type: GrantFiled: December 22, 2014Date of Patent: March 7, 2017Assignee: Unimatec Co., Ltd.Inventors: Satoru Saito, Katsuyuki Sato, Takehiro Sonoi
-
Patent number: 9587040Abstract: Process for the preparation of solid particles of a magnesium-chloride alcohol adduct comprising (a) forming an emulsion between a MgCl2 .alcohol adduct in molten form and a liquid phase which is immiscible with the said adduct in the presence of a polyalkyl-methacrylate used as a solution having viscosity ranging from 100 to 5000 mm2/s and (b) rapidly cooling the emulsion to solidify the disperse phase and collecting the solid adduct particles.Type: GrantFiled: April 13, 2012Date of Patent: March 7, 2017Assignee: Basell Poliolefine Italia S.r.l.Inventors: Benedetta Gaddi, Daniele Evangelisti, Gianni Collina
-
Patent number: 9587041Abstract: The present invention provides a solid organomagnesium precursor having formula {Mg(OR?)X}.a{MgX2}.b{Mg(OR?)2}.c{R?OH}, wherein R? is selected from a hydrocarbon group, X is selected from a halide group, and a:b:c is in range of 0.01-0.5:0.01-0.5:0.01-5 and process for preparing the same, said process comprising contacting a magnesium source with a solvating agent, an organohalide and an alcohol to obtain the solid organomagnesium precursor. The present invention also provides a process for preparing a catalyst system using the organomagnesium precursor and its use thereof for polymerization of olefins. The organomagnesium precursor is prepared as follows: At 0° C., magnesium in diethyl ether is reacted with the organohalide. After all magnesium has reacted, the calculated amount of alcohol was added and after the completion of addition, the ether was evaporated and a solid compound obtained.Type: GrantFiled: September 24, 2013Date of Patent: March 7, 2017Assignee: INDIAN OIL CORPORATION LIMITEDInventors: Sukhdeep Kaur, Gurmeet Singh, Bhasker Bantu, Naresh Kumar, Gurpreet Singh Kapur, Shashi Kant, Biswajit Basu, Ravinder Kumar Malhotra
-
Patent number: 9587042Abstract: An object of the present invention is to provide a process for producing a modified conjugated diene-based polymer suitable for preparing a polymer composition excellent in the fuel cost saving effect. The present invention provides a process for producing a modified conjugated diene-based polymer, comprising reacting a conjugated diene-based polymer having a monomer unit based on a conjugated diene compound and a monomer unit based on a compound represented by the following formula (1), with an organometallic compound, and reacting the resulting reaction product with a hydrocarbyloxysilane compound: wherein R11, R12, R13, R14 and R15 each represent a hydrogen atom or an alkyl group, at least one of R11, R12, R13, R14 and R15 is an alkyl group, R16, R17 and R18 each represent a hydrogen atom or a hydrocarbyl group, R19 represents a hydrocarbylene group, and k represents 0 or 1.Type: GrantFiled: March 27, 2012Date of Patent: March 7, 2017Assignee: SUMITOMO CHEMICAL COMPANY, LIMITEDInventor: Mana Ito
-
Patent number: 9587043Abstract: A crosslinkable and crosslinked polymer composition with improved DC electrical properties and a cable surrounded by at least one layer comprising the polymer composition are provided.Type: GrantFiled: November 3, 2010Date of Patent: March 7, 2017Assignee: BOREALIS AGInventors: Ulf Nilsson, Annika Smedberg, Alfred Campus
-
Patent number: 9587044Abstract: Polypropylene having a melt flow rate MFR2 (230° C.) of at least 20 g/10 min; and a Mw/Mn ratio of at least 15.0.Type: GrantFiled: June 10, 2014Date of Patent: March 7, 2017Assignee: Borealis AGInventors: Norbert Hafner, Klaus Bernreitner, Marcus Gahleitner
-
Patent number: 9587045Abstract: The present invention relates to the use of polyamidohydroxamates in washing and cleaning agents to improve cleaning performance, in particular with regard to stains containing polymerizable dyes.Type: GrantFiled: March 6, 2014Date of Patent: March 7, 2017Assignee: Henkel AG & Co. KGaAInventors: Christian Kropf, Benoit Luneau, Siglinde Erpenbach, Andre Hatzelt, Thomas Weber
-
Patent number: 9587046Abstract: Disclosed are a photocurable composition which includes (A) a photocurable monomer and (B) a monomer represented by Formula 1, and an apparatus including a protective layers formed of the composition;Type: GrantFiled: June 12, 2013Date of Patent: March 7, 2017Assignee: CHEIL INDUSTRIES, INC.Inventors: Chang Min Lee, Seung Jib Choi, Ji Hye Kwon, Kyoung Jin Ha, Yeon Soo Lee